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INHERITED COLON CANCERS
Grobbelaar et al.' and Ramesar et al.' (in this issue) have
identified germline mutations in certain families with h"o
different types of inherited colorectal cancers. This means that
blood tests are now available in South Africa for clinical use in
these particular families. Within the families these DNA-based
tests can separate individuals with the mutation that causes
cancer from those who do not have it. Those with a mutation
may pass the family-specific mutation to their children.
Hereditary non-polyposis colon cancer (HNPCC) accounts
for bemeen 1% and 6% of all colorectal cancers.3", Familial
adenomatous polyposis (FAP), although better known,
accounts for approximately 1%. These MO forms of familial
colorectal cancer have a dominant. inheritance pattern. The
D A tests do not apply to most patients with colorectal cancers
(sporadic), or to patients with colorectal cancer who have close
relatives with the disease but no clearly defined inheritance
pattern.
The hvo types of inherited colarectal cancer have very
different clinical features. Although the colorectal cancers
associated with HNPCC follow the usual polyp-cancer
sequence, very few polyps develop. The disease has two
identifiable forms: a site-specific form (Lynch I) that is confined
to the colon, and a site-nonspecific form (Lynch II) where
family members may in addition develop cancers at other sites
including the stomach, urinary tract, small intestine, biliary
system, ovary, pancreas, breast, and endometrium.' Colonic
cancers associated with H JPCC typically manifest in patients
in their forties, are often multiple and are more commonly.
situated in the proximal colon 6 FAP is characterised by the
development of multiple colonic polyps during the late teens
or early menties, and with the development of colorectal
cancer in the third decade.? Colorectal cancer will develop in
more than 90% of individuals who have a mutation in the gene
underlying either HNPCC or FAP.
The studies of Grobbelaar et al.' and Ramesar et al.' have
shown that with the availability of new mutation detection
techniques it is now simpler to detect new mutations within
families. Testing will therefore become more readily available.
It is important that these tests are used correctly as there are
consequences that are not immediately obvious.
The implications that arise from mutation testing within a
family should not be underestimated. The emotions resulting
from test results can include anger in those who test positive,
While those who test negative may be overwhelmed by guilt
for escaping a disease that affects a do e relative. Testing
positive may also have financial implications regarding life and
medical insurance. Knowledge of mutation status is extremely
useful for those who test negative, as they can be reassured and
discharged from medical care. The advantage, however, for
those who test positive is the potential prevention of cancer.
Because of these factors, consent for genetic testing is an
extremely important issue. It is essential that individuals at risk
for these diseases are counselled by a qualified genetics
counsellor before testing and that they undergo post-test
counselling when the results are released. The Nuffield
Council" and the British Medical Association'recommend that
individuals who undergo testing should be of an age where
they are legally responsible and have adequate understanding
of the issues involved in both positive and negative test results.
Dickenson lO argues that testing of individuals younger than 18
years of age should be performed provided that the individual
requests testing and has adequate understanding of the
implications of the test results. Should an individual choose to
have a genetic test, a genetics counsellor should release the
result, in writing and verbally during the post-test counselling
session. Results should not be released to anyone else (family
members, doctors or insurance companies), unless the tested
individual authorises this in writing.
How, then, should these diseases be managed now that
genetic testing is available?
HEREDITARY NON-POLYPOSIS COLORECTAL
CANCER
An accurate family history is the best clinical method of
detecting H JPCe. Surveillance of individuals at 50% risk by
examination of the family tree (or pedigree analysis) should
begin at age 25 or at least 5 years before the earliest cancer
onset in that family." Colonoscopy is the only effective
surveillance tool for colonic lesions because the tumuurs tend
to be proximal." In addition to colonoscopy, regular
mammography, abdominal ultrasound and endometrial
sampling are needed for those individuals who belong to
families with the site-nonspecific form of the disease.
In H PCC more than five genes are known to underlie the
more common forms of the disorder. For this reason it is
advisable to submit families suspected of having H PCC for
research so that a 'designer' test for that specific family can be
developed. Usually blood (or pathological specimens) from at
least three affected individuals and an equal number of
unaffected first-degree relatives (older than 50 years) is
required to lead researchers to the gene that is involved in a
particular family. The relevant gene is then investigated
thoroughly for disease-causing mutations. Once the biological
effect of the mutation has been confirmed through its tracking
with all affected individual, pre ymptomatic mutation t ting
hould only be offered to family members who have reached
the age of legal consent. Pre- and post-test counselling by a
qualified geneti counsellor i es ntial. Individual who test
negative can be rea ured and discharged from follow-up.
Tho who choo e not to be t ted and those who test positive
'hould be entered into a urveillance programme with
lono py performed every 2 - 3 Y r until the ri k of dying
from oth r eau es ex eed the risk of dying from colorcctal
cancer."
Prophylactic cole tomy for mutation-po itive individuals is
not yet establi hed management. This i because the risks
a!>sociat d with colonoscopy are much lower than those of
surgery and polypectomy may prevent the development of
cancer. Total colectomy with ilea-rectal anastomosi may
become a candidate operation in thi group of patient becau e
r ctal cancer is uncommon."
FAMILIAL ADE OMATOUS POLYPOSIS
At-risk family members should undergo an initial rigid or
flexible sigmoido copy in their early teens. If sigmoidoscopy is
negative, then it should be repeated every 2 year untill
years of age. If biopsy-proven adenomatou polyps are
identified, prophylactic surgery should be considered. Thi
may be delayed until the individual finishes school becau e the
risk of cancer is low in young asymptomatic individuals.
Individual hould be offered genetic testing by a qualified
genetics counsellor once they have attained the age of legal
consent. If the individual test negative for the family-specific
mutation, he/ he can be rea ured and discharged from further
medical care. Individuals who te t positive hould continue to
undergo regular sigmoidoscopic examinations at 2-yearly
intervals. Individual who do not wish to undergo genetic
te ting should have sigmoidoscopy every 2 years until they are
-15 years old, or longer if the family has late-onset disease.
Famili with a known mutation and a history of early onset of
cancer hould be treated according to the clinical trend of that
specific mutation.
The role of prophylactic sur ery, limitation of family size, use
of donor gamete, pre-implantation diagnosis and selective
termination of pregnane ba ed on prenatal diagno i will
become clearer with experience.
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